Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that results from the Phase III ...
Adding carboplatin to standard neoadjuvant chemotherapy improves overall survival in TNBC, but the benefit is only ...
Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrexed as a first-line treatment in patients with unresectable, locally advanced or ...
Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...
ELAHERE® receives a positive recommendation by Canada's Drug Agency (CDA-AMC) ELAHERE ® was submitted for reimbursement review 180 days prior to Health ...
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
TORONTO, Oct. 30, 2025 /CNW/ - Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance ...
Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...
Niraparib significantly improved PFS and time without symptoms for women with advanced ovarian cancer who responded to ...
Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment for advanced penile cancer in a phase 2 trial. The results were published in JAMA Oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback